|Videos|January 8, 2021
C. Difficile Treatment: Bezlotoxumab
The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Advertisement
Advertisement
Trending on Contagion Live
1
US Company Recalls Thousands of Pounds of Uninspected Meat
2
Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions
3
How The Food Safety Surveillance Infrastructure Works in the US
4
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
5